Moderna Submits Application To FDA For Review Of Spikevax 2024-2025 Formula Targeting SARS-CoV-2 Variant JN.1
Portfolio Pulse from Benzinga Newsdesk
Moderna has submitted an application to the FDA for the review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 variant JN.1.
June 07, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna has submitted an application to the FDA for the review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 variant JN.1. This could lead to increased demand and revenue if approved.
The submission of the application to the FDA is a significant step for Moderna. If the Spikevax formula is approved, it could lead to increased demand and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100